Filtered By:
Condition: Pulmonary Hypertension

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 621 results found since Jan 2013.

Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news

Janssen ’s Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations
TITUSVILLE, NJ, November 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first impact summary for its Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now multi-year initiative, designed to create urgency and action around the hidden threat of peripheral artery disease (PAD)-related amputation. In its inaugural year, Save Legs. Change Lives.™ focused on reaching Black Americans, who are up to four times more likely than white Americans to have a PAD-related amputation.1 With this critical initiative, Janssen is focused on helping those at risk of PAD through more th...
Source: Johnson and Johnson - November 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Continuous Positive Airway Pressure Therapy for Sleep Apnea: A Newly Controversial Topic
Until recently, treatment for obstructive sleep apnea (OSA) was not a controversial topic. Untreated OSA is associated with increased rate of myocardial infarction, stroke, hyperlipidemia, hypertension, diabetes, and arrhythmias, including atrial fibrillation and pulmonary hypertension, to mention just a few of its most significant associated conditions. Because continuous positive airway pressure (CPAP) is a safe and effective treatment to reduce sleep apnea, it has been assumed for decades to reduce associated cardiovascular risks.
Source: Sleep Medicine Clinics - November 2, 2022 Category: Sleep Medicine Authors: Matthew R. Ebben Tags: Preface Source Type: research

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

HIV, Subclinical Cardiovascular Disease, and Clinical Progression
People living with HIV have higher risks of cardiovascular disease (CVD) including myocardial infarction, heart failure, stroke, pulmonary hypertension, and sudden cardiac death than those without HIV. These excess CVD risks persist in the modern HIV treatment era and are not readily explained by demographic, environmental, or clinical confounding factors. Nor are these HIV-associated CVD risks explained by antiretroviral therapy (ART); the net cardiovascular and overall benefits of effective HIV treatment clearly outweigh the risks. Thus, refining HIV-specific contributors to CVD pathogenesis is critically important for i...
Source: JAMA - September 13, 2022 Category: General Medicine Source Type: research

Elevated plasma WIF ‐1 levels are associated with worse prognosis in heart failure with pulmonary hypertension
ConclusionsThe present study demonstrated that LHF-PH patients have higher plasma WIF-1 levels than healthy controls, suggesting that plasma WIF-1 may be a potential future prognostic biomarker in LHF-PH. Its prognostic capability could be further refined by including it in a multi-marker panel. Further studies are needed to establish the potential role of WIF-1 in LHF-PH pathophysiology in larger cohorts to determine its clinical applicability.
Source: ESC Heart Failure - September 9, 2022 Category: Cardiology Authors: Kriss Kania, Abdulla Ahmed, Salaheldin Ahmed, G öran Rådegran Tags: Original Article Source Type: research

Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
CONCLUSIONS: HIF stabiliser management of anaemia had uncertain effects on CV death, fatigue, death (any cause), CV outcomes, and kidney failure compared to placebo or ESAs. Compared to placebo or ESAs, HIF stabiliser management of anaemia probably decreased the proportion of patients requiring blood transfusions, and probably increased the proportion of patients reaching the target Hb when compared to placebo.PMID:36005278 | DOI:10.1002/14651858.CD013751.pub2
Source: Cochrane Database of Systematic Reviews - August 25, 2022 Category: General Medicine Authors: Patrizia Natale Suetonia C Palmer Allison Jaure Elisabeth M Hodson Marinella Ruospo Tess E Cooper Deirdre Hahn Valeria M Saglimbene Jonathan C Craig Giovanni Fm Strippoli Source Type: research

Prognostic value of computer tomography derived measurements of pulmonary artery diameter on long term outcomes after transcatheter aortic valve replacement
CONCLUSION: PAD >29.3 mm in baseline MDCT is associated with higher 1-year mortality after TAVR, independently of echocardiographic measure of PH and frailty.PMID:35892248 | DOI:10.33963/KP.a2022.0173
Source: Polish Heart Journal - July 27, 2022 Category: Cardiology Authors: Łukasz Kalińczuk Zbigniew Chmielak Maciej D ąbrowski Marcin Mazurkiewicz Patrycjusz Stok łosa Wiktor Skotarczak Gary S Mintz Rafa ł Wolny Pawe ł Tyczyński Marek Konka Anna Micha łowska Ilona Kowalik Marcin Demkow Ilona Micha łowska Adam Witkowski Source Type: research

New Approaches for Enhancement of the Efficacy of Mesenchymal Stem Cell-Derived Exosomes in Cardiovascular Diseases
Tissue Eng Regen Med. 2022 Jul 22. doi: 10.1007/s13770-022-00469-x. Online ahead of print.ABSTRACTCardiovascular diseases (CVDs) remain a major health concern worldwide, where mesenchymal stem cells (MSCs) therapy gives great promise in their management through their regenerative and paracrine actions. In recent years, many studies have shifted from the use of transplanted stem cells to their secreted exosomes for the management of various CVDs and cardiovascular-related diseases including atherosclerosis, stroke, myocardial infarction, heart failure, peripheral arterial diseases, and pulmonary hypertension. In different m...
Source: Atherosclerosis - July 22, 2022 Category: Cardiology Authors: Lamiaa Ahmed Khaled Al-Massri Source Type: research

Exercise and hypoxia unmask pulmonary vascular disease and right ventricular dysfunction in a 10-12  week old swine model of neonatal oxidative injury
In conclusion, duration of neonatal hypoxia appears an important determinant of alterations in cardiopulmonary function that persist further into life. These changes encompass both the pulmonary vasculature, and the response of the heart to hypoxia and exercise. Abstract figure legend Exposure of Neonatal Swine to hypoxia for up to four weeks resulted in an increase in pulmonary vascular resistance (PVR) and right ventricular hypertrophy that persisted after recovery in normoxia. Exercise experiments revealed an increased dependency on nitric oxide (NO) to maintain a PVR low, as well as a reduced stroke volume (SV) during ...
Source: The Journal of Physiology - July 21, 2022 Category: Physiology Authors: Jarno J Steenhorst Alexander Hirsch Annemarie Verzijl Piotr Wielopolski Daphne de Wijs-Meijler Dirk J Duncker Irwin K M Reiss Daphne Merkus Source Type: research